Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N‐terminal pro B‐type natriuretic peptide levels-Reference-Cited by-同舟云学术

Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N‐terminal pro B‐type natriuretic peptide levels

Published:2020-12-05 Issue:1 Volume:44 Page:85-90
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Pandey Amitabh C.¹²^ORCID,Jer Derek³,Kuo Ruth S.³,Yoo David H.¹,Christophy Antonio¹⁴,Mohan Rajeev C.¹⁴,Srivastava Ajay V.¹⁴,Heywood James Thomas¹⁴

Affiliation:

1. Division of Cardiology Scripps Prebys Cardiovascular Institute, Scripps Clinic La Jolla California USA

2. Scripps Research Translational Institute The Scripps Research Institute La Jolla California USA

3. Department of Pharmacy Scripps Clinic La Jolla California USA

4. Section of Advanced Heart Failure and Mechanical Circulatory Support, Division of Cardiology Scripps Prebys Cardiovascular Institute, Scripps Clinic La Jolla California USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.23509

Reference22 articles.

1. Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

2. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction

3. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

4. Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials

5. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study;Indian Journal of Clinical Cardiology;2024-03-22

2. Efficacy and safety of sacubitril/valsartan after six months in patients with heart failure with reduced ejection fraction and asymptomatic hypotension;Journal of Geriatric Cardiology;2023-12

3. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction;Frontiers in Cardiovascular Medicine;2023-03-22

4. Efficacy and safety of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension;2023-02-22

5. Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis;2023-02-10